Pentraxin 3 is reduced in bipolar disorder
Objective Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population. Methods Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non‐psychiatric controls. Linear regress...
Gespeichert in:
| Veröffentlicht in: | Bipolar disorders 2015-06, Vol.17 (4), p.409-414 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 414 |
|---|---|
| container_issue | 4 |
| container_start_page | 409 |
| container_title | Bipolar disorders |
| container_volume | 17 |
| creator | Dickerson, Faith Stallings, Cassie Origoni, Andrea Katsafanas, Emily Schweinfurth, Lucy AB Savage, Christina LG Khushalani, Sunil Yolken, Robert |
| description | Objective
Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population.
Methods
Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non‐psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group.
Results
The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = −3.78, p |
| doi_str_mv | 10.1111/bdi.12281 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1686416123</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1686416123</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3631-5811f672f24c4e9169c099e3fed4a24b972308bb366c85b522e8dd588baa7a793</originalsourceid><addsrcrecordid>eNp1kF9PwjAUxRujEUQf_AJmj2oyWNutax8VBTGoJP5LfGna9S6pDoYti_DtHQx88-Ym99zkd87DQegUR11cT08b28WEcLyH2pgKESYM8_2N5rWO0xY68v4zijAjUXKIWiSJ14vb6HICs4VTSzsLaGB94MBUGZig_rWdl4VygbG-dAbcMTrIVeHhZHs76HVw-9K_C8dPw1H_ahxmlFEcJhzjnKUkJ3EWg8BMZJEQQHMwsSKxFimhEdeaMpbxRCeEADcm4VwrlapU0A46b3LnrvyuwC_k1PoMikLNoKy8xIyzGDNMaI1eNGjmSu8d5HLu7FS5lcSRXFcj62rkppqaPdvGVnoK5o_cdVEDvQb4sQWs_k-S1zejXWTYOKxfwPLPodyXZClNE_n-OJQfb4M-uX94lhP6C2eHeeQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1686416123</pqid></control><display><type>article</type><title>Pentraxin 3 is reduced in bipolar disorder</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Dickerson, Faith ; Stallings, Cassie ; Origoni, Andrea ; Katsafanas, Emily ; Schweinfurth, Lucy AB ; Savage, Christina LG ; Khushalani, Sunil ; Yolken, Robert</creator><creatorcontrib>Dickerson, Faith ; Stallings, Cassie ; Origoni, Andrea ; Katsafanas, Emily ; Schweinfurth, Lucy AB ; Savage, Christina LG ; Khushalani, Sunil ; Yolken, Robert</creatorcontrib><description>Objective
Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population.
Methods
Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non‐psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group.
Results
The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = −3.78, p < 0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates.
Conclusions
Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.</description><identifier>ISSN: 1398-5647</identifier><identifier>EISSN: 1399-5618</identifier><identifier>DOI: 10.1111/bdi.12281</identifier><identifier>PMID: 25425421</identifier><language>eng</language><publisher>Denmark: Blackwell Publishing Ltd</publisher><subject>Adult ; Biomarkers - blood ; bipolar disorder ; Bipolar Disorder - diagnosis ; Bipolar Disorder - immunology ; Bipolar Disorder - psychology ; C-Reactive Protein - analysis ; Female ; Humans ; Immunity, Innate - immunology ; innate immunity ; Male ; Middle Aged ; pentraxin 3 ; Reference Values ; schizophrenia ; Schizophrenia - diagnosis ; Schizophrenia - immunology ; Serum Amyloid P-Component - analysis</subject><ispartof>Bipolar disorders, 2015-06, Vol.17 (4), p.409-414</ispartof><rights>2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3631-5811f672f24c4e9169c099e3fed4a24b972308bb366c85b522e8dd588baa7a793</citedby><cites>FETCH-LOGICAL-c3631-5811f672f24c4e9169c099e3fed4a24b972308bb366c85b522e8dd588baa7a793</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbdi.12281$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbdi.12281$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25425421$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dickerson, Faith</creatorcontrib><creatorcontrib>Stallings, Cassie</creatorcontrib><creatorcontrib>Origoni, Andrea</creatorcontrib><creatorcontrib>Katsafanas, Emily</creatorcontrib><creatorcontrib>Schweinfurth, Lucy AB</creatorcontrib><creatorcontrib>Savage, Christina LG</creatorcontrib><creatorcontrib>Khushalani, Sunil</creatorcontrib><creatorcontrib>Yolken, Robert</creatorcontrib><title>Pentraxin 3 is reduced in bipolar disorder</title><title>Bipolar disorders</title><addtitle>Bipolar Disord</addtitle><description>Objective
Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population.
Methods
Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non‐psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group.
Results
The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = −3.78, p < 0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates.
Conclusions
Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.</description><subject>Adult</subject><subject>Biomarkers - blood</subject><subject>bipolar disorder</subject><subject>Bipolar Disorder - diagnosis</subject><subject>Bipolar Disorder - immunology</subject><subject>Bipolar Disorder - psychology</subject><subject>C-Reactive Protein - analysis</subject><subject>Female</subject><subject>Humans</subject><subject>Immunity, Innate - immunology</subject><subject>innate immunity</subject><subject>Male</subject><subject>Middle Aged</subject><subject>pentraxin 3</subject><subject>Reference Values</subject><subject>schizophrenia</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - immunology</subject><subject>Serum Amyloid P-Component - analysis</subject><issn>1398-5647</issn><issn>1399-5618</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kF9PwjAUxRujEUQf_AJmj2oyWNutax8VBTGoJP5LfGna9S6pDoYti_DtHQx88-Ym99zkd87DQegUR11cT08b28WEcLyH2pgKESYM8_2N5rWO0xY68v4zijAjUXKIWiSJ14vb6HICs4VTSzsLaGB94MBUGZig_rWdl4VygbG-dAbcMTrIVeHhZHs76HVw-9K_C8dPw1H_ahxmlFEcJhzjnKUkJ3EWg8BMZJEQQHMwsSKxFimhEdeaMpbxRCeEADcm4VwrlapU0A46b3LnrvyuwC_k1PoMikLNoKy8xIyzGDNMaI1eNGjmSu8d5HLu7FS5lcSRXFcj62rkppqaPdvGVnoK5o_cdVEDvQb4sQWs_k-S1zejXWTYOKxfwPLPodyXZClNE_n-OJQfb4M-uX94lhP6C2eHeeQ</recordid><startdate>201506</startdate><enddate>201506</enddate><creator>Dickerson, Faith</creator><creator>Stallings, Cassie</creator><creator>Origoni, Andrea</creator><creator>Katsafanas, Emily</creator><creator>Schweinfurth, Lucy AB</creator><creator>Savage, Christina LG</creator><creator>Khushalani, Sunil</creator><creator>Yolken, Robert</creator><general>Blackwell Publishing Ltd</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201506</creationdate><title>Pentraxin 3 is reduced in bipolar disorder</title><author>Dickerson, Faith ; Stallings, Cassie ; Origoni, Andrea ; Katsafanas, Emily ; Schweinfurth, Lucy AB ; Savage, Christina LG ; Khushalani, Sunil ; Yolken, Robert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3631-5811f672f24c4e9169c099e3fed4a24b972308bb366c85b522e8dd588baa7a793</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adult</topic><topic>Biomarkers - blood</topic><topic>bipolar disorder</topic><topic>Bipolar Disorder - diagnosis</topic><topic>Bipolar Disorder - immunology</topic><topic>Bipolar Disorder - psychology</topic><topic>C-Reactive Protein - analysis</topic><topic>Female</topic><topic>Humans</topic><topic>Immunity, Innate - immunology</topic><topic>innate immunity</topic><topic>Male</topic><topic>Middle Aged</topic><topic>pentraxin 3</topic><topic>Reference Values</topic><topic>schizophrenia</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - immunology</topic><topic>Serum Amyloid P-Component - analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dickerson, Faith</creatorcontrib><creatorcontrib>Stallings, Cassie</creatorcontrib><creatorcontrib>Origoni, Andrea</creatorcontrib><creatorcontrib>Katsafanas, Emily</creatorcontrib><creatorcontrib>Schweinfurth, Lucy AB</creatorcontrib><creatorcontrib>Savage, Christina LG</creatorcontrib><creatorcontrib>Khushalani, Sunil</creatorcontrib><creatorcontrib>Yolken, Robert</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Bipolar disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dickerson, Faith</au><au>Stallings, Cassie</au><au>Origoni, Andrea</au><au>Katsafanas, Emily</au><au>Schweinfurth, Lucy AB</au><au>Savage, Christina LG</au><au>Khushalani, Sunil</au><au>Yolken, Robert</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pentraxin 3 is reduced in bipolar disorder</atitle><jtitle>Bipolar disorders</jtitle><addtitle>Bipolar Disord</addtitle><date>2015-06</date><risdate>2015</risdate><volume>17</volume><issue>4</issue><spage>409</spage><epage>414</epage><pages>409-414</pages><issn>1398-5647</issn><eissn>1399-5618</eissn><abstract>Objective
Immunologic abnormalities have been found in bipolar disorder but pentraxin 3, a marker of innate immunity, has not been studied in this population.
Methods
Levels of pentraxin 3 were measured in individuals with bipolar disorder, schizophrenia, and non‐psychiatric controls. Linear regression models were used to compare the pentraxin 3 levels in each of the psychiatric groups to that in the control group, adjusting for demographic and clinical variables. Logistic regression models were used to calculate the odds ratios associated with levels of pentraxin 3 which differed from specified levels of the control group.
Results
The sample consisted of 831 individuals: 256 with bipolar disorder, 309 with schizophrenia, and 266 without a psychiatric disorder. The levels of pentraxin 3 in the bipolar disorder, but not in the schizophrenia, group were significantly lower than those of controls, adjusting for age, gender, race, maternal education, smoking status, and body mass index (t = −3.78, p < 0.001). The individuals with bipolar disorder also had significantly increased odds of having low levels of pentraxin 3 relative to both the 10th and 25th percentile level of the controls and significantly decreased odds of having a level greater than the 75th and the 90th percentile level of the controls, adjusting for the same covariates.
Conclusions
Individuals with bipolar disorder have low levels of pentraxin 3 which may reflect impaired innate immunity. An increased understanding of the role of innate immunity in the etiopathogenesis of bipolar disorder might lead to new modalities for the diagnosis and treatment of this disorder.</abstract><cop>Denmark</cop><pub>Blackwell Publishing Ltd</pub><pmid>25425421</pmid><doi>10.1111/bdi.12281</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1398-5647 |
| ispartof | Bipolar disorders, 2015-06, Vol.17 (4), p.409-414 |
| issn | 1398-5647 1399-5618 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1686416123 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Biomarkers - blood bipolar disorder Bipolar Disorder - diagnosis Bipolar Disorder - immunology Bipolar Disorder - psychology C-Reactive Protein - analysis Female Humans Immunity, Innate - immunology innate immunity Male Middle Aged pentraxin 3 Reference Values schizophrenia Schizophrenia - diagnosis Schizophrenia - immunology Serum Amyloid P-Component - analysis |
| title | Pentraxin 3 is reduced in bipolar disorder |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T23%3A50%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pentraxin%203%20is%20reduced%20in%20bipolar%20disorder&rft.jtitle=Bipolar%20disorders&rft.au=Dickerson,%20Faith&rft.date=2015-06&rft.volume=17&rft.issue=4&rft.spage=409&rft.epage=414&rft.pages=409-414&rft.issn=1398-5647&rft.eissn=1399-5618&rft_id=info:doi/10.1111/bdi.12281&rft_dat=%3Cproquest_cross%3E1686416123%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1686416123&rft_id=info:pmid/25425421&rfr_iscdi=true |